Skip to Main Content

A Translational and Neurocomputational Evaluation of a Dopamine Receptor 1 Partial Agonist for Schizophrenia

Conditions

Mental Health & Behavioral Research

Phase I-II

What is the purpose of this trial?

This study will test whether CVL-562 (PF-06412562), a dopamine 1 partial agonist novel compound, affects working memory neural circuits in patients with early episode schizophrenia. The overall aim is to establish neuroimaging biomarkers of the Dopamine Receptor 1/Dopamine Receptor 5 Family (D1R/D5R) target engagement to accelerate development of D1R/D5R agonists in humans to treat cognitive impairments that underlie functional disability in schizophrenia, a key unaddressed clinical and public health concern.

  • Trial with
    National Institute of Mental Health/NIH/DHHS
  • Start Date
    11/10/2020
  • End Date
    12/31/2023

For more information about this study, contact:

Schizophrenia Neuropharmacology Research Group at Yale (SNRGY)

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    06/02/2022
  • Study HIC
    #2000027506